H
Huamin Wang
Researcher at University of Texas MD Anderson Cancer Center
Publications - 325
Citations - 24532
Huamin Wang is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 76, co-authored 289 publications receiving 20411 citations. Previous affiliations of Huamin Wang include University of Texas at Austin & Mary Bird Perkins Cancer Center.
Papers
More filters
Journal ArticleDOI
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Andrea Viale,Piergiorgio Pettazzoni,Costas A. Lyssiotis,Haoqiang Ying,Nora S. Sanchez,Matteo Marchesini,Alessandro Carugo,Tessa Green,Sahil Seth,Virginia Giuliani,Maria Kost-Alimova,Florian L. Muller,Simona Colla,Luigi Nezi,Giannicola Genovese,Angela K. Deem,Avnish Kapoor,Wantong Yao,Emanuela Brunetto,Ya'an Kang,Min Yuan,John M. Asara,Y. Alan Wang,Timothy P. Heffernan,Alec C. Kimmelman,Huamin Wang,Jason B. Fleming,Lewis C. Cantley,Ronald A. DePinho,Giulio Draetta +29 more
TL;DR: It is demonstrated that a subpopulation of dormant tumour cells surviving oncogene ablation (surviving cells) and responsible for tumour relapse has features of cancer stem cells and relies on oxidative phosphorylation for survival.
Journal ArticleDOI
Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
Thiruvengadam Arumugam,Vijaya Ramachandran,Keith Fournier,Huamin Wang,Lauren Marquis,James L. Abbruzzese,Gary E. Gallick,Craig D. Logsdon,David J. McConkey,Woonyoung Choi +9 more
TL;DR: In this article, the authors characterized patterns of sensitivity and resistance to three conventional chemotherapeutic agents with divergent mechanisms of action [gemcitabine, 5-fluorouracil (5-FU), and cisplatin] in pancreatic cancer cells.
Journal ArticleDOI
Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy
Gauri R. Varadhachary,Eric P. Tamm,James L. Abbruzzese,Henry Q. Xiong,Christopher H. Crane,Huamin Wang,Jeffrey E. Lee,Peter W.T. Pisters,Douglas B. Evans,Robert A. Wolff +9 more
TL;DR: Patients with favorable responses to preoperative therapy are the subset of patients who have the best chance for an R0 resection and a favorable long-term outcome.
Journal ArticleDOI
Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head
Douglas B. Evans,Gauri R. Varadhachary,Christopher H. Crane,Charlotte C. Sun,Jeffrey E. Lee,Peter W.T. Pisters,Jean Nicolas Vauthey,Huamin Wang,Karen R. Cleary,Gregg A Staerkel,Chusilp Charnsangavej,Elizabeth A. Lano,Linus Ho,Renato Lenzi,James L. Abbruzzese,Robert A. Wolff +15 more
TL;DR: The encouraging overall survival observed in this large trial supports the continued investigation of gemcitabine-based preoperative therapy in resectable pancreatic cancer.
Journal ArticleDOI
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Avnish Kapoor,Wantong Yao,Haoqiang Ying,Sujun Hua,Alison Liewen,Qiuyun Wang,Yi Zhong,Chang-Jiun Wu,Anguraj Sadanandam,Anguraj Sadanandam,Baoli Hu,Qing Chang,Gerald C. Chu,Ramsey Al-Khalil,Shan Jiang,Hongai Xia,Eliot Fletcher-Sananikone,Carol Lim,Gillian I. Horwitz,Andrea Viale,Piergiorgio Pettazzoni,Nora S. Sanchez,Huamin Wang,Alexei Protopopov,Jianhua Zhang,Timothy P. Heffernan,Randy L. Johnson,Lynda Chin,Y. Alan Wang,Giulio Draetta,Ronald A. DePinho +30 more
TL;DR: It is shown that some tumors undergo spontaneous relapse and are devoid of Kras(G12D) expression and downstream canonical MAPK signaling and instead acquire amplification and overexpression of the transcriptional coactivator Yap1.